UK reimbursement authority NICE has recommended that the NHS in England can use AstraZeneca's Imfinzi as the first ...
Health secretary’s ‘power grab’ to override Nice comes amid growing concern move may be illegal and benefit big pharma ...
A new UK drug approval pathway, designed to speed up the availability of new medicines, benefits industry over patients and ...
Medicines watchdog approves two treatments for patients with spinal muscular atrophy ...
UCB's Rystiggo can be used by the NHS as a backup treatment for people with the rare autoimmune and neuromuscular disease generalised myasthenia gravis who don't respond well enough to standard ...
A new UK drug approval pathway, designed to speed up the availability of new medicines, benefits industry over patients and ...
‘Breakthrough’ drug for severe muscle wasting condition set for NHS rollout in England - Givinostat will be made available to eligible patients with Duchenne muscular dystrophy after its manufacturer ...
Pharmaceutical Technology on MSN
Imfinzi set to become first immunotherapy for stomach cancer patients on NHS
AstraZeneca’s targeted treatment helps patients live longer, along with preventing cancer recurrence.
If there's one thing I'm sick of, it's liberals and their radical views on how math works. So I'm glad RFK Jr. took time to explain Trump Math.
Pharma stocks are gaining momentum as obesity drugs, oncology therapies and biotech innovation boost investor optimism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results